Extraneal
- Procedure started
- Under evaluation
- CHMP opinion
- European Commission final decision
Table of contents
Overview
The European Medicines Agency has completed an arbitration procedure for Extraneal 7.5% solution for peritoneal dialysis. The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that the change to the marketing authorisation for Extraneal to include a peptidoglycan test can be granted, and that the use of the active substance icodextrin sourced from one of the currently approved manufacturers should cease.
The review was carried out under an 'Article 6(12)' referral1
The European Commission issued a decision on 10 January 2010.
1 Article 6(12) of Regulation (EC) 1084/2003 as amended, referral on a variation to a marketing authorisation
Key facts
Approved name |
Extraneal
|
International non-proprietary name (INN) or common name |
icodextrin |
Reference number |
CHMP/683039/2009
|
Type |
Article 6(12) referrals (prior to January 2010)
This type of referral was triggered for a medicine that had been authorised by mutual recognition or via the decentralised procedure when there was disagreement between Member States on a variation (type II). This referral has been replaced by Article 13 referrals. |
Status |
European Commission final decision
|
Opinion date |
22/10/2009
|
EC decision date |
20/01/2010
|
All documents
-
List item
Questions and answers on the referral for Extraneal icodextrin 7.5% solution for peritoneal dialysis (PDF/32.74 KB)
Adopted
First published: 27/10/2009
Last updated: 10/02/2010
EMEA/CHMP/683039/2009 -
-
List item
Extraneal - Article 6(12) referral - Annex I, II, III, IV (PDF/35.23 KB)
Adopted
First published: 10/02/2010
Last updated: 10/02/2010 -
Document description
- Questions and answers (Q&A) - easy-to-understand summary of key issues and Committee conclusions
- Summary of Opinion - contains the CHMP opinion of the referred medicine(s)
- List of the medicines affected by the referral (Annex I)
- Scientific conclusions of the Committee (Annex II)
The following two documents are sometimes available:
- Changes to the summary of product characteristics, labeling or package leaflet (also known as Annex III) - available when changes havebeen recommended by the Committee
- Conditions of the marketing authorisation (also known as Annex IV) - available when the Committee recommends measures to be takenfor the marketing authorisation(s) such as safety measures or extra studies